Statistical Considerations in the Design of Biosimilar Cancer Clinical Trials
نویسندگان
چکیده
منابع مشابه
Statistical Considerations in the Design of Biosimilar Cancer Clinical Trials.
When the patent of an innovative (brand-name) small-molecule drug expires, generic copies of the innovative drug may be marketed if their therapeutic equivalence to the innovative drug has been shown. The small-molecule drugs are considered therapeutically equivalent and can be used interchangeably if two drugs are shown to be pharmaceutically equivalent with identical active substance and bioe...
متن کاملClinical considerations for biosimilar antibodies
Biosimilar agents are approximate copies of branded biologic therapies. Since the first biosimilar was authorized in the European Union in 2006, fifteen additional agents have been approved by the European Medicines Agency, including two biosimilar monoclonal antibodies (mAbs). Biosimilar mAbs represent a distinct class given their large molecular size, complex protein structure, and post-trans...
متن کاملStatistical considerations in the design, conduct and analyses of antiemetic clinical trials. An emerging consensus.
Various aspects of trial design and planning for clinical testing of antiemetic therapies administered to cancer patients are considered. It is generally felt that a randomized double-blind parallel-arm design is the best. Ways of achieving adequate power of such studies are discussed briefly, as is the need for previous identification of primary and secondary end-points. Finally, summary recom...
متن کاملConsiderations in the design of clinical trials for erectile dysfunction
The naissance of the phosphodiesterase-5 inhibitors has dramatically fueled the research engine in pursuit of novel therapies for erectile dysfunction (ED). The epidemiological product of reports on penile implants, to multicenter, randomized, double-blinded, placebo-controlled trials on oral therapy and intracavernosal/intraurethral injection therapy, has translated into substantial assets for...
متن کاملStatistical considerations in biosimilar assessment using biosimilarity index.
When an innovative biologic product goes off patent, biopharmaceutical or biotechnological companies may file an application for regulatory approval of biosimilar products. Unlike small molecule drug products, biosimilars are not exact copies of their brand-name counterpart, and they are usually very sensitive to changes in environmental factors and have greater variabilities due to their compl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Korean Journal of Applied Statistics
سال: 2011
ISSN: 1225-066X
DOI: 10.5351/kjas.2011.24.3.495